SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, and Retro Biosciences (Retro), a ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Hilary Brueck Every time Hilary publishes a story, you’ll get an alert straight to your inbox!

OpenAI CEO Sam Altman’s longevity startup Retro Bio is seeking to raise a $5 billion valuation, which could make it one of the drug industry’s biggest investment rounds. The startup’s goal is to add ...

Gilead Sciences secured the rights to Sprint Bioscience’s preclinical oncology program for up to $400 million. Iolyx Therapeutics announced a strategic partnership with Laboratoires Théa, valued at up ...

The team behind Retro Bio, a longevity startup backed by OpenAI CEO Sam Altman, is close to raising what could be one of the drug industry’s largest investment rounds. And although the company doesn’t ...